US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Argen X NV

619.44

0.0000

Volume:- -

Turnover:- -

Market Cap:37.04B

PE:-178.66

High:619.44

Open:619.44

Low:619.44

Close:619.44

52wk High:697.42

52wk Low:525.60

Shares:59.80M

Float Shares:59.40M

Volume Ratio:0.05

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.4672

EPS(LYR):-5.1610

ROE:24.72%

ROA:4.83%

PB:6.08

PE(LYR):-120.02

Loading ...

Overview Company News Filings

Is Argenx SE (ARGX) the Best Performing Biotech Stock in 2024?

Here’s Why argenx SE (ARGX) Surged in Q3

Should You Increase Your Holdings in argenx SE (ARGX)?

Three Stocks Estimated To Be Undervalued In December 2024

Simply Wall St.

Why Is Argenx SE (ARGX) Among the Best High Growth Healthcare Stocks to Invest In Now?

Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ARGNF/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARGNF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARGNF\",,,,,undefined,":{"symbol":"ARGNF","market":"US","secType":"STK","nameCN":"Argen X NV","latestPrice":619.437,"timestamp":1755892800000,"preClose":619.437,"halted":0,"volume":0,"delay":15,"floatShares":59396720,"shares":59796273,"eps":-3.467175,"marketStatus":"Market Closed","change":0,"latestTime":"08-22 16:00:00 EDT Delay","open":619.437,"high":619.437,"low":619.437,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-3.467175,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1756108800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":619.437,"volumeRatio":0.05208308919385274},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARGNF\",,,,,undefined,":{"symbol":"ARGNF","floatShares":59396720,"roa":"4.83%","roe":"24.72%","lyrEps":-5.161043,"volumeRatio":0.05208308919385274,"shares":59796273,"dividePrice":0,"high":619.437,"amplitude":0,"preClose":619.437,"low":619.437,"week52Low":525.6012,"pbRate":"6.08","psRate":"11.87","week52High":697.42,"institutionHeld":0,"latestPrice":619.437,"eps":-3.467175,"divideRate":0,"volume":0,"delay":15,"ttmEps":-3.467175,"open":619.437,"prevYearClose":652.35,"prevWeekClose":619.437,"prevMonthClose":547.6,"prevQuarterClose":547.18,"fiveDayClose":619.437,"twentyDayClose":547.6,"sixtyDayClose":562},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARGNF\",params:#limit:5,,,undefined,":[{"date":"2024-05-09","symbol":"ARGNF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715241600000,"name":null,"time":"Pre-Market","dateTimestamp":1715227200000,"actualEps":null},{"market":"US","date":"2022-10-27","symbol":"ARGNF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1666843200000,"reportTimeType":"pre","actualEps":null},{"date":"2022-05-12","symbol":"ARGNF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1652342400000,"name":null,"time":"","dateTimestamp":1652328000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARGNF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARGNF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3158,"buy":0.6842,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6842,"analysts":19,"updateTime":1754366400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARGNF\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2493678757","title":"Is Argenx SE (ARGX) the Best Performing Biotech Stock in 2024?","url":"https://stock-news.laohu8.com/highlight/detail?id=2493678757","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493678757?lang=en_us&edition=fundamental","pubTime":"2024-12-23 23:28","pubTimestamp":1734967734,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024.In this article, we are going to take a look at where Argenx SE  stands against the other biotech stocks.Biotech businesses have been further challenged by volatile market conditions, which have led several of them to reduce programs and lay off huge numbers of employees to save money. Although recent rate cuts may assist in resurrecting scientific initiatives, analysts like Jared Holz point out that it is still challenging to forecast their consequences. Holz also points out that the performance of biotech companies is increasingly matching that of small-cap stocks, indicating a change in market dynamics. Biotech may increase if small-cap stocks trade well, but stagnation could result from momentum loss. Interest rates and biotech success have a relatively recent relationship that emerged after the pandemic when enterprises with a therapeutic focus received","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bxfdqe1EH4820KHsBTcffQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/5e12869f7fd21716d91f9d66b55c0bcb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bxfdqe1EH4820KHsBTcffQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/5e12869f7fd21716d91f9d66b55c0bcb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argenx-se-argx-best-performing-152854506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","QID","BK4505","BK4159",".IXIC","PSQ","NVIW.SI","USAW.SI","CAGR","TQQQ","LU0109394709.USD","SQQQ","NQmain","ARGNF","LU0320765992.SGD","TSYW.SI","USJW.SI","BK4585","LU0889565916.HKD","MNQmain","ARGX","QLD","BK4588"],"gpt_icon":1},{"id":"2490847543","title":"Here’s Why argenx SE (ARGX) Surged in Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2490847543","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490847543?lang=en_us&edition=fundamental","pubTime":"2024-12-12 22:30","pubTimestamp":1734013844,"startTime":"0","endTime":"0","summary":"PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. Given concerns regarding the decreasing pace of U.S. employment and the associated concerns that U.S. interest rates may have been maintained at levels higher than necessary to moderate the pace of inflation, U.S. equity markets fluctuated during the summer and partially reversed their year-to-date gains. The S&P 1500 Health Care Index appreciated 6.1% in the third quarter, outperforming the S&P 500, which gained 5.9%. While the fund advanced in the quarter, it underperformed the index. Stock selection within medtech and pharmaceuticals contributed to the most value. Relative performance was negatively impacted by security selection in biotechnology and health care providers and services, as well as underweights in life sciences tools and services. In addition, please check the fund’s top five holdings to know its best picks in 2024.PGIM Jennison Hea","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mt8gqOqXXFsuAtOU9VjozQ--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/5058430d0581cc2eecf09dc6586066c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mt8gqOqXXFsuAtOU9VjozQ--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/5058430d0581cc2eecf09dc6586066c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-argenx-se-argx-surged-143044713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","TQQQ","BK4585","SQQQ","BK4123","NQmain","NVIW.SI","IE0031619046.USD","MG","USJW.SI","QID","IE00B7SZL793.SGD","LU0109394709.USD","ARGNF","QLD","ARGX","BK4505","LU0320765992.SGD","LU0889565916.HKD","BK4588","BK4139","PSQ","IE00B66KJ199.SGD","IE00B19Z4B17.USD","MNQmain",".IXIC","USAW.SI"],"gpt_icon":1},{"id":"2490784157","title":"Should You Increase Your Holdings in argenx SE (ARGX)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2490784157","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490784157?lang=en_us&edition=fundamental","pubTime":"2024-12-09 22:10","pubTimestamp":1733753413,"startTime":"0","endTime":"0","summary":"TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. Within equities, smaller or value-oriented stocks in developed economies yielded higher, whereas emerging markets saw the opposite trend. In the third quarter, the strategy returned 4.96%  and 4.75%  while the Russell Midcap Growth Index returned 6.54%. In addition, please check the fund’s top five holdings to know its best picks in 2024.TimesSquare Capital U.S. Mid Cap Growth Strategy highlighted stocks like Argenx SE  in the Q3 2024 investor letter. Argenx SE  is a biotechnology company focused on autoimmune diseases. The one-month return of Argenx SE  was 5.80%, and its shares gained 37.40% of their value over the last 52 weeks. On December 6, 2024, Argenx SE  stock closed at $623.11 per share with a market capitalization of $37.26 billion.TimesSquare Capital U.S. Mid Cap Growth Strategy state","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mt8gqOqXXFsuAtOU9VjozQ--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/5058430d0581cc2eecf09dc6586066c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mt8gqOqXXFsuAtOU9VjozQ--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/5058430d0581cc2eecf09dc6586066c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/increase-holdings-argenx-se-argx-141013864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0889565916.HKD","ARGX","MNQmain","ARGNF","TQQQ","QID","QLD","BK4139",".IXIC","BK4588","LU0109394709.USD","PSQ","NQmain","BK4585","BK4505","LU0320765992.SGD","SQQQ"],"gpt_icon":1},{"id":"2488696894","title":"Three Stocks Estimated To Be Undervalued In December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2488696894","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488696894?lang=en_us&edition=fundamental","pubTime":"2024-12-03 12:06","pubTimestamp":1733198787,"startTime":"0","endTime":"0","summary":"As global markets continue to reach record highs, driven by strong gains in major indices like the Dow Jones Industrial Average and S&P 500, investors are navigating a landscape influenced by geopolitical developments and domestic policy shifts. Amidst this environment, identifying undervalued stocks can offer potential opportunities for those looking to capitalize on discrepancies between market price and intrinsic value.Click here to see the full list of 900 stocks from our Undervalued Stocks Based On Cash Flows screener.Operations: The company's revenue segments are distributed as follows: Sweco UK with SEK1.48 billion, Sweco Norway at SEK3.48 billion, Sweco Sweden contributing SEK8.88 billion, Sweco Belgium at SEK3.99 billion, Sweco Denmark with SEK3.38 billion, Sweco Finland generating SEK3.62 billion, Sweco Netherlands at SEK3.28 billion, and Sweco Germany & Central Europe providing SEK2.78 billion in revenue.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/three-stocks-estimated-undervalued-december-040627130.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0109394709.USD","BK4588","ARGX","ARGNF","LU0320765992.SGD","BK4585","BK4139","BK4505","LU0889565916.HKD"],"gpt_icon":0},{"id":"2488945968","title":"Why Is Argenx SE (ARGX) Among the Best High Growth Healthcare Stocks to Invest In Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2488945968","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488945968?lang=en_us&edition=fundamental","pubTime":"2024-12-03 03:55","pubTimestamp":1733169338,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a look at where Argenx SE  stands against the other high growth healthcare stocks.This year, the pharmaceutical, medical equipment and supplies, robotics, biotechnology, and neurodegenerative illnesses sub-spaces are the primary ones to watch in the healthcare industry. The emergence and development of glucagon-like Peptide-1 agonists  is the primary trend of interest in the pharmaceutical industry. These treatments have had a substantial impact on weight loss medications and have completely altered the competitive landscape in this field. Pharmaceutical companies that sell weight-loss medications have also benefited from higher prescription volumes and sales as a result of the development of GLP-1s. For example, BlackRock reported that from 2019 to August 2023, GLP-1 prescription volumes increased at a compound annual growth rate of 45%. The development of Ozempi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bxfdqe1EH4820KHsBTcffQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/5e12869f7fd21716d91f9d66b55c0bcb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bxfdqe1EH4820KHsBTcffQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/5e12869f7fd21716d91f9d66b55c0bcb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-argenx-se-argx-among-195538109.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QID","QLD","TQQQ","LU0889565916.HKD","BK4505","BK4139","HCSG","GDP","BK4213","BK4585","LU1894683264.USD","LU2637428348.USD","ARGX","BK4208","ARGNF","MNQmain","PSQ",".IXIC","SQQQ","LU2346227817.USD","CMS","LU1894683348.USD","LU0109394709.USD","BK4588","BK4137","NQmain","LU0320765992.SGD"],"gpt_icon":1},{"id":"2484766486","title":"Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2484766486","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484766486?lang=en_us&edition=fundamental","pubTime":"2024-11-18 22:10","pubTimestamp":1731939059,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now.In this article, we are going to take a look at where argenx SE  stands against the other immunotherapy stocks.The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by 2033. The growth is driven by the global rise in chronic diseases such as different types of cancer, autoimmune diseases, and infections.Cancer, particularly is becoming more prevalent among people globally. The American Cancer Society recently released its 2024 Global Cancer Statistics report, which highlights the increasing burden of cancer worldwide. In 2022 alone, approximately 20 million new cancer cases were diagnosed, and 9.7 million people died from the disease. By 2050, annual cancer cases are expected to reach 35 million, driving demand for innovative treatments like immunotherapy.Immunotherapy offers a promising alternative to traditional therapies, and its applic","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bxfdqe1EH4820KHsBTcffQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/5e12869f7fd21716d91f9d66b55c0bcb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bxfdqe1EH4820KHsBTcffQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/5e12869f7fd21716d91f9d66b55c0bcb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argenx-se-argx-best-immunotherapy-141059445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0889565916.HKD","QID","ARGX","LU0320765992.SGD","BK4585","ARGNF","BK4588","BK4139",".IXIC","BK4505","SQQQ","LU0109394709.USD","NQmain","QLD","TQQQ","MNQmain","PSQ"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":26,"code":"91000000","status":"200"}]}}